Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has issued an announcement.
SynAct Pharma AB released its interim report for the second quarter of 2025, highlighting significant events and financial developments. The company continues to focus on its research and development efforts in inflammatory diseases, which could impact its market positioning and stakeholder interests.
More about SynAct Pharma AB
SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation using melanocortin biology.
Average Trading Volume: 205,153
Technical Sentiment Signal: Sell
Current Market Cap: SEK929.2M
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.